Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates

Infection and Immunity

Volumn 82, Issue 3, 2014, Pages 1157-1163

  van der Veen, Stijn ^a   Johnson, Steven ^a   Jongerius, Ilse ^a   Malik, Talat ^b   Genovese, Alessia ^c   Santini, Laura ^c   Staunton, David ^d   Ufret Vincenty, Rafael L ^e   Pickering, Matthew C ^b   Lea, Susan M ^a   Tang, Christoph M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; EPITOPES; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEISSERIA MENINGITIDIS; PROTEIN BINDING;

EID: 84894248640     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01183-13     Document Type: Article

References (41)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388. http://dx.doi.org /10.1056/NEJM200105033441807.
2. Stephens DS, Greenwood B, Brandtzaeg P. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210. http://dx.doi.org/10.1016/S0140-6736(07)61016-2.
3. Caugant DA. 2008. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect. Genet. Evol. 8:558-565. http://dx.doi.org/10.1016/j.meegid.2008.04.002.
4. Christensen H, May M, Bowen L, Hickman M, Trotter CL. 2010. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10:853-861. http://dx.doi.org/10.1016/S1473-3099 (10)70251-6.
5. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240. http://dx.doi.org/10.1016/j.tim.2007.03.005.
6. Stephens DS. 1999. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 353:941-942. http://dx.doi.org/10.1016/S0140-6736 (98)00279-7.
7. Andersen BM. 1978. Mortality in meningococcal infections. Scand. J. Infect. Dis. 10:277-282.
8. Sharip A, Sorvillo F, Redelings MD, Mascola L, Wise M, Nguyen DM.2006. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr. Infect. Dis. J. 25:191-194. http://dx .doi.org/10.1097/01.inf.0000202065.03366.0c.
9. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
10. Jennings HJ, Lugowski C. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
11. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Safadi MA. 2012. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(Suppl 2): B26-B36. http://dx.doi.org/10.1016/j.vaccine.2011.12.032.
12. Harrison LH, Trotter CL, Ramsay ME. 2009. Global epidemiology of meningococcal disease. Vaccine 27(Suppl 2):B51-B63. http://dx.doi.org /10.1016/j.vaccine.2009.04.063.
13. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, Jolley KA, Maiden MC, Heuberger S, Frosch M. 2007. A surveillance network for meningococcal disease in Europe. FEMS Microbiol. Rev. 31: 27-36. http://dx.doi.org/10.1111/j.1574-6976.2006.00060.x.
14. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799. http://dx.doi.org/10.1084/jem .20021911.
15. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ. 2012. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307:573-582. http://dx.doi.org/10.1001/jama.2012.85.
16. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garces-Sanchez M, Martinon-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL. 2012. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 12:597-607. http://dx .doi.org/10.1016/S1473-3099(12)70087-7.
17. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, Dull PM. 2012. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379:617-624. http://dx.doi.org/10.1016/S0140-6736(11)61713-3.
18. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL. 2013. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 31:1569-1575. http://dx .doi.org/10.1016/j.vaccine.2013.01.021.
19. Bai X, Findlow J, Borrow R. 2011. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin. Biol. Ther. 11:969-985. http://dx.doi.org/10.1517/14712598.2011 .585965.
20. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893. http://dx.doi.org /10.1038/nature07769.
21. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100. http://dx.doi.org/10.1128/IAI .72.4.2088-2100.2004.
22. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389. http://dx.doi.org/10.1086/600141.
23. Pajon R, Beernink PT, Harrison LH, Granoff DM. 2010. Frequency of factor H-binding protein modular groups and susceptibility to crossreactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129. http://dx.doi.org/10.1016/j.vaccine.2009.12.027.
24. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW. 2011. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29:4739-4744. http://dx.doi.org/10.1016/j.vaccine .2011.04.092.
25. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A, DiMarcello F, Marchi S, van der Ende A, Arico B, Savino S, Scarselli M, Comanducci M, Rappuoli R, Giuliani MM, Pizza M. 2011. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect. Immun. 79:970-981. http://dx.doi .org/10.1128/IAI.00891-10.
26. de Cordoba SR, de Jorge EG. 2008. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin. Exp. Immunol. 151:1-13. http://dx.doi.org/10 .1111/j.1365-2249.2007.03552.x.
27. Perkins SJ, Nan R, Li K, Khan S, Miller A. 2012. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology 217:281-297. http://dx.doi.org/10.1016/j .imbio.2011.10.003.
28. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
29. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575.
30. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D. 2009. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol. Immunol. 46:1647-1653. http://dx.doi.org/10.1016/j.molimm.2009.02.021.
31. Malito E, Faleri A, Lo Surdo P, Veggi D, Maruggi G, Grassi E, Cartocci E, Bertoldi I, Genovese A, Santini L, Romagnoli G, Borgogni E, Brier S, Lo Passo C, Domina M, Castellino F, Felici F, van der Veen S, Johnson S, Lea SM, Tang CM, Pizza M, Savino S, Norais N, Rappuoli R, Bottomley MJ, Masignani V. 2013. Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc. Natl. Acad. Sci. U. S. A. 110:3304-3309. http://dx.doi .org/10.1073/pnas.1222845110.
32. Vu DM, Pajon R, Reason DC, Granoff DM. 2012. A broadly cross-reactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Sci. Rep. 2:341. http://dx.doi.org/10.1038/srep00341.
33. Johnson S, Tan L, van der Veen S, Caesar J, Goicoechea De Jorge E, Harding RJ, Bai X, Exley RM, Ward PN, Ruivo N, Trivedi K, Cumber E, Jones R, Newham L, Staunton D, Ufret-Vincenty R, Borrow R, Pickering MC, Lea SM, Tang CM. 2012. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog. 8:e1002981. http://dx.doi.org/10.1371 /journal.ppat.1002981.
34. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606-3614. http://dx.doi.org/10.4049/jimmunol .1003470.
35. Pajon R, Beernink PT, Granoff DM. 2012. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect. Immun. 80:2667-2677. http://dx.doi.org/10 .1128/IAI.00103-12.
36. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769. http://dx.doi.org/10.1128/IAI.01191-08.
37. Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, De Tora L, Pizza M, Rappuoli R, van de Beek D, van der Ende A, Comanducci M. 2013. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBAover a 50-year period in the Netherlands. PLoS One 8:e65043. http: //dx.doi.org/10.1371/journal.pone.0065043.
38. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Borrow R.2010. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol. 17:919-929. http://dx.doi.org/10.1128/CVI.00027-10.
39. Greenfield NJ. 2006. Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 1:2876-2890. http://dx.doi.org/10.1038 /nprot.2006.202.
40. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D. 2006. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093-5107. http://dx.doi.org/10.1016/j.vaccine .2006.03.091.
41. Jongerius I, Lavender H, Tan L, Ruivo N, Exley RM, Caesar JJ, Lea SM, Johnson S, Tang CM. 2013. Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein. PLoS Pathog. 9:e1003528. http://dx.doi.org/10.1371/journal.ppat .1003528.